New hope for rare ovarian cancer: immunotherapy drug tested in small trial
NCT ID NCT05737199
First seen Nov 01, 2025 · Last updated Jun 06, 2026 · Updated 35 times
Summary
This study tests the drug pembrolizumab in 21 women with a rare and advanced form of ovarian cancer called squamous cell carcinoma. The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants receive the drug intravenously, and the study tracks how many respond and how long they live without the cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Niigata University Medical & Dental Hosptal
Niigata, Niigata, 951-8510, Japan
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.